Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa
|
journal
|
May 2008 |
Designing and Testing Broadly-Protective Filoviral Vaccines Optimized for Cytotoxic T-Lymphocyte Epitope Coverage
|
journal
|
October 2012 |
A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance
|
journal
|
April 2016 |
The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence
|
journal
|
July 2016 |
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
|
journal
|
June 2009 |
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
|
journal
|
November 2013 |
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
|
journal
|
September 2012 |
Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques
|
journal
|
May 2016 |
Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection
|
journal
|
March 2016 |
Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains
|
journal
|
June 2014 |
Cytomegalovirus Vectors Violate CD8+ T Cell Epitope Recognition Paradigms
|
journal
|
May 2013 |
Justification for the inclusion of Gag in HIV vaccine candidates
|
journal
|
December 2015 |
Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine
|
journal
|
October 2007 |
T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces
|
journal
|
May 2009 |
Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys
|
journal
|
February 2010 |
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
|
journal
|
April 2012 |
The role of recombination in the emergence of a complex and dynamic HIV epidemic
|
journal
|
March 2010 |
Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys
|
journal
|
October 2013 |
HIV-1 Conserved Elements p24CE DNA Vaccine Induces Humoral Immune Responses with Broad Epitope Recognition in Macaques
|
journal
|
October 2014 |
A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies
|
journal
|
September 2013 |
Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens
|
journal
|
March 2016 |
Early Low-Titer Neutralizing Antibodies Impede HIV-1 Replication and Select for Virus Escape
|
journal
|
May 2012 |
Optimization and delivery of plasmid DNA for vaccination
|
journal
|
December 2006 |
HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
|
journal
|
March 1996 |
Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults
|
journal
|
January 2008 |
New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency
|
journal
|
October 2015 |
Definition of the viral targets of protective HIV-1-specific T cell responses
|
journal
|
January 2011 |
Nanoparticle vaccines
|
journal
|
January 2014 |
Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein
|
journal
|
June 2015 |
HIV-1 Nomenclature Proposal
|
journal
|
April 2000 |
Burden of tuberculosis at post mortem in inpatients at a tertiary referral centre in sub-Saharan Africa: a prospective descriptive autopsy study
|
journal
|
May 2015 |
Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection
|
journal
|
April 2016 |
Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies
|
journal
|
December 2013 |
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design
|
journal
|
December 2015 |
Recent Developments in Preclinical DNA Vaccination
|
journal
|
January 2014 |
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
|
journal
|
August 2015 |
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
|
journal
|
April 2013 |
Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition
|
journal
|
February 2016 |
Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies
|
journal
|
October 2015 |
Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody
|
journal
|
April 2016 |
Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E
|
journal
|
January 2016 |
Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIV SF162P3N -Infected Macaques
|
journal
|
February 2016 |
Translating HIV Sequences into Quantitative Fitness Landscapes Predicts Viral Vulnerabilities for Rational Immunogen Design
|
journal
|
March 2013 |
Antibody responses to envelope glycoproteins in HIV-1 infection
|
journal
|
May 2015 |
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants
|
journal
|
December 2006 |
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
|
journal
|
November 2008 |
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
|
journal
|
December 2009 |
Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies
|
journal
|
August 2016 |
Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
|
journal
|
July 2010 |
Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site
|
journal
|
May 2015 |
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study
|
journal
|
May 2014 |
Distinct Evolutionary Pressures Underlie Diversity in Simian Immunodeficiency Virus and Human Immunodeficiency Virus Lineages
|
journal
|
October 2012 |
Hepatitis C Genotype 1 Mosaic Vaccines Are Immunogenic in Mice and Induce Stronger T-Cell Responses than Natural Strains
|
journal
|
December 2012 |
Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G
|
journal
|
May 2016 |
Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies
|
journal
|
July 2014 |
Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV
|
journal
|
December 2013 |
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
|
journal
|
November 2008 |
Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants
|
journal
|
October 2015 |
Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys
|
journal
|
February 2010 |
Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E
|
journal
|
June 2006 |
Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost
|
journal
|
April 2015 |
Antiretroviral Treatment of Adult HIV Infection: 2014 Recommendations of the International Antiviral Society–USA Panel
|
journal
|
July 2014 |
Nanotechnology in vaccine delivery
|
journal
|
May 2008 |
Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing
|
journal
|
August 2010 |
HIV-1 Vaccine Development After STEP
|
journal
|
February 2010 |
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine
|
journal
|
May 2011 |
Impact of HIV infection on the haemostatic response during sepsis and malaria
|
journal
|
March 2016 |
Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors
|
journal
|
June 2015 |
Progress in HIV-1 vaccine development
|
journal
|
July 2014 |
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120
|
journal
|
May 2013 |
Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial
|
journal
|
July 2014 |
Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale
|
journal
|
August 2014 |
Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing
|
journal
|
August 2011 |
Vaccine delivery using nanoparticles
|
journal
|
January 2013 |
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|
journal
|
September 2016 |
Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens
|
journal
|
July 2012 |
Web-based design and evaluation of T-cell vaccine candidates
|
journal
|
May 2008 |
Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine
|
journal
|
October 2016 |
Diversity Considerations in HIV-1 Vaccine Selection
|
journal
|
June 2002 |
Polyreactivity and Autoreactivity among HIV-1 Antibodies
|
journal
|
October 2014 |
T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load: Immunity to infection
|
journal
|
October 2012 |
Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.
|
journal
|
January 1995 |
Nanotechnology in vaccine delivery
|
journal
|
May 2008 |
First Steps toward a Globally Effective HIV/AIDS Vaccine
|
journal
|
October 2013 |
B Cell Liaison Confounds HIV-1 Evolution
|
journal
|
July 2014 |
Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody
|
journal
|
April 2016 |
Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G
|
journal
|
May 2016 |
Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies
|
journal
|
August 2016 |
HIV-1 Vaccines: Let’s Get Physical
|
journal
|
March 2013 |
Progress in HIV-1 vaccine development
|
journal
|
July 2014 |
Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults
|
journal
|
January 2008 |
Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E
|
journal
|
June 2006 |
Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens
|
journal
|
July 2012 |
Tuberculosis burden at post mortem
|
journal
|
October 2015 |
Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition
|
journal
|
February 2016 |
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine
|
journal
|
May 2011 |
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
|
journal
|
September 2012 |
Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV
|
journal
|
December 2013 |
Antibody responses to envelope glycoproteins in HIV-1 infection
|
journal
|
May 2015 |
Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys
|
journal
|
February 2010 |
Another HIV vaccine failure: where to next?
|
journal
|
December 2013 |
Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies
|
journal
|
October 2015 |
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants
|
journal
|
December 2006 |
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120
|
journal
|
May 2013 |
Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine
|
journal
|
October 2016 |
Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains
|
journal
|
June 2014 |
Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques
|
journal
|
May 2016 |
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
|
journal
|
June 2009 |
Persistent HIV-1 replication during antiretroviral therapy
|
journal
|
January 2016 |
Impact of HIV infection on the haemostatic response during sepsis and malaria
|
journal
|
March 2016 |
Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
|
journal
|
July 2010 |
Cytomegalovirus Vectors Violate CD8+ T Cell Epitope Recognition Paradigms
|
journal
|
May 2013 |
HIV-1 Nomenclature Proposal
|
journal
|
April 2000 |
Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein
|
journal
|
June 2015 |
Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E
|
journal
|
January 2016 |
Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses
|
journal
|
May 2016 |
Full-Length HIV-1 Immunogens Induce Greater Magnitude and Comparable Breadth of T Lymphocyte Responses to Conserved HIV-1 Regions Compared with Conserved-Region-Only HIV-1 Immunogens in Rhesus Monkeys
|
journal
|
August 2012 |
Early initiation of antiretroviral therapy prevents HIV transmission to seronegative sexual partners
|
journal
|
November 2016 |
HIV-1 Vaccine Development After STEP
|
journal
|
February 2010 |
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape
|
journal
|
December 2012 |
Definition of the viral targets of protective HIV-1-specific T cell responses
|
journal
|
January 2011 |
The role of recombination in the emergence of a complex and dynamic HIV epidemic
|
journal
|
March 2010 |
Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine
|
journal
|
October 2007 |
Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing
|
journal
|
August 2010 |
Designing and Testing Broadly-Protective Filoviral Vaccines Optimized for Cytotoxic T-Lymphocyte Epitope Coverage
|
journal
|
October 2012 |
Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial
|
journal
|
July 2014 |
HIV-1 Conserved Elements p24CE DNA Vaccine Induces Humoral Immune Responses with Broad Epitope Recognition in Macaques
|
journal
|
October 2014 |
Early Low-Titer Neutralizing Antibodies Impede HIV-1 Replication and Select for Virus Escape
|
journal
|
May 2012 |
A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies
|
journal
|
September 2013 |
Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site
|
journal
|
May 2015 |
Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection
|
journal
|
March 2016 |
Justification for the inclusion of Gag in HIV vaccine candidates
|
journal
|
December 2015 |
Optimization and delivery of plasmid DNA for vaccination
|
journal
|
December 2006 |
Vaccine delivery using nanoparticles
|
journal
|
January 2013 |
Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants
|
journal
|
October 2015 |
Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies
|
journal
|
December 2013 |
Recent Developments in Preclinical DNA Vaccination
|
journal
|
January 2014 |
Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens
|
journal
|
March 2016 |
The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence
|
journal
|
July 2016 |